Table 1.
Clinicopathological data for 10 samples of pediatric ALL
| Patient's number/Variable* | Sex Age (years) | Peripheral blood/Bone marrow | De novo/ Relapsed | Pre-B cell/ T cell | Cytogenetics** | Response to RG7388 |
| ALL 269 | Boy (2) | Peripheral blood | De novo | Pre-B cell | No | Sensitive |
| ALL 270 | Girl (2) | Bone marrow | De novo | Pre-B cell | No | Sensitive |
| ALL 271 | Boy (3) | Bone marrow | De novo | Pre-B cell | No | Resistant |
| ALL 272 | Girl (5) | Peripheral blood | Relapsed | Pre-B cell | No | Resistant |
| ALL 273 | Boy (9) | Bone marrow | Relapsed | T cell | No | Resistant |
| ALL 274 | Boy (6) | Bone marrow | De novo | Pre-B cell | T (12, 21)/ETV6-RUNX1 | Sensitive |
| ALL 275 | Girl (3) | Peripheral blood | De novo | Pre-B cell | T (1, 19)/TCF3-PBX1 | Sensitive |
| ALL 276 | Girl (5) | Peripheral blood | De novo | Pre-B cell | No | Sensitive |
| ALL 277 | Girl (5) | Peripheral blood | Relapsed | T cell | No | Resistant |
| ALL 278 | Boy (12) | Peripheral blood | De novo | Pre-B cell | No | Sensitive |
*The blast proportion for all patients’ samples was over 70%. **The most common cytogenetics (T (4; 11)/KMT2A-AFF1, T (9; 22)/BCR-ABL1, T (1; 19)/ TCF3-PBX1, T (12; 21)/ ETV6-RUNX1) were only analyzed.